Affiliation:
1. Department of Nuclear Medicine, Weifang People's Hospital, Shandong Province, People's Republic of China.
Abstract
Abstract
An 84-year-old man with prostate cancer with neuroendocrine differentiation underwent PET/CT for staging. 68Ga–prostate-specific membrane antigen PET/CT did not show significant abnormal tracer accumulation, whereas 18F-OC (18F-AlF-NOTA-octreotide) PET/CT showed elevated tracer uptake at multiple sites throughout the body. Therefore, the patient opted to receive 1 cycle of 177Lu-DOTATATE peptide receptor radionuclide therapy with a dose of 200 mCi. Encouragingly, radiographic tumor remission and improvement of clinical symptoms were observed after only 1 cycle of treatment.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献